Tazifylline (also known as LN 2974) is a long-acting histamine H1-receptor antagonist that was studied in clinical trials for the treatment of allergic rhinitis and asthma. In addition, this compound was studied on the itching and scratching of patients with atopic eczema. However, the further development of tazifylline appears to have been discontinued by Roche.

Brazergoline is a sympatholytic and antihypertensive agent that was used as a vasodilator. It was studied as a component of a condom with an erectogenic composition. In addition, brazergoline, as a vasoactive agent was studied for the treatment of female sexual dysfunction.

GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK. GSK-923295 inhibited release of inorganic phosphate and stabilized CENP-E motor domain interaction with microtubules. Inhibition of CENP-E motor activity in cultured cells and tumor xenografts caused failure of metaphase chromosome alignment and induced mitotic arrest, indicating that tight binding of CENP-E to microtubules is insufficient to satisfy the mitotic checkpoint. Consistent with genetic studies in mice suggesting that decreased CENP-E function can have a tumor-suppressive effect, inhibition of CENP-E induced tumor cell apoptosis and tumor regression.

Pridopidine is an experimental drug candidate belonging to a class of agents known as dopidines, which act as dopaminergic stabilizers in the central nervous system. As a dopamine stabilizer, pridopidine is thought to reduce the effects of dopamine when there’s too much and increase its effects when there’s too little. Pridopidine, therefore, plays two opposing roles in the brain, which stabilize dopamine levels. In this way, pridopidine is thought to help the brain reestablish a normal balance of neurotransmitters, and thus regain control over motion. Pridopidine intended to treat Huntington’s disease movement symptoms. Pridopidine was well tolerated and had an adverse event profile similar to a placebo.

Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections

Ioseric Acid is triiodoisophthalamic acid derivative patented by Schering A.-G. as x-ray contrast media

Froxiprost (ONO-995), a synthetic analog of dinoprost, is a prostanoid receptor agonist. Froxiprost is active in contracting the uterine smooth muscle and is used as a pharmacological tool.

Fuprazole was developed as a bronchodilator that has never been marketed. Information about the current use of this compound is not available.

Fluperlapine is dibenzazepine chemically and pharmacologically similar to clozapine. Fluperlapine had no cataleptogenic effect and did not inhibit the apomorphine- and d-amphetamine-induced stereotypes. Fluperlapine is fairly effective neuroleptic drug with a fast-acting antipsychotic affect. The effects in movement disorders imply that fluperlapine is less liable than traditional neuroleptics to induce acute extrapyramidal side effects and tardive dyskinesia and is particularly beneficial in the treatment of patients vulnerable to neurological side-effects. It was demonstrated efficacy in the treatment of a variety of medical conditions including schizophrenia, psychosis associated with Parkinson's disease and dystonia. It has the capacity for producing life-threatening agranulocytosis.